Rathmell: We need a “March Madness” for cancer research

“Cancer is a tremendously challenging tournament, but we are in it to win”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The views expressed here are those of Kimryn Rathmell alone.

Dear Colleagues,

Although this column is running in The Cancer Letter, where we turn for timely insights and information relevant to the cancer community, I suspect that a lot of our readers are watching college basketball this week. 

After all, March Madness, or the NCAA college basketball tournament to determine the national championship, has become an annual event at colleges, living rooms, and sports bars around the U.S. Even those who don’t follow the sport during the season track their favorite school—their alma mater, or a school with their favorite stellar cancer center —to see how far they go. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

Curebound has announced eight grants for a total of $2 million in funding. The funding is made available through two new Curebound programs: Catalyst Grants, which support projects within early-stage life science companies that are seeking to take innovative discoveries to commercially approved products, and Equity Grants, which focus on overcoming disparities in cancer research and treatment in underserved populations.
Xavier Apolinarski (left), vice president of innovation at Université Paris-Saclay, and Eric Durand (right), chief research and technology officer at Owkin at the signing of the deal between Université Paris-Saclay and Owkin.Université Paris-Saclay and Owkin announce the signing of a memorandum of understanding to explore the potential of K Pro Free—Owkin’s AI co-pilot for biology—for use by Université Paris-Saclay.
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login